Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...

Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an ...

Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 13.67%, which has investors questioning if this is right time to ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo (NYSE: WFC) ...

Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...

Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable ...

Wells Fargo upgraded Regulus (RGLS) to Overweight from Equal Weight with a price target of $6, up from $3.Light Up your Portfolio with ...

Soleno Therapeutics SLNO shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. Ocean Biomedical OCEA shares moved upwards by 23.05% ...

The number of Woodford investors joining RGL Management's campaign against Hargreaves Lansdown has surpassed 8,300 ...